Cargando…
AB110. Efficacy and safety of mTOR inhibitor in the treatment of renal cell cancer: a meta-analysis
BACKGROUND: Treatment for metastatic renal cell cancer (mRCC) has advanced dramatically with understanding of the pathogenesis of the disease. New treatment options may provide improved median progression-free survival (MPFS). We aimed to determine the relative effectiveness of new therapies in this...
Autores principales: | Zhang, Keke, Yan, Fei, Wang, Fuli, Yuan, Jianlin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708334/ http://dx.doi.org/10.3978/j.issn.2223-4683.2014.s110 |
Ejemplares similares
-
AB98. The study of cell proliferation and apoptosis and autophagy in renal cell carcinoma cells influence by the PI3K/AKT/mTor inhibitor NVP-BEZ235
por: Li, Hong-Yan, et al.
Publicado: (2014) -
AB108. Vascularized bone marrow transplantation with renal transplantation
por: Wei, Di, et al.
Publicado: (2014) -
AB116. Clinical efficacy and safety of molecular targeted drugs as first-line treatment for mRCC: a systematic review and network meta-analysis
por: Mo, Chengqiang, et al.
Publicado: (2014) -
AB124. Modified retroperitoneoscopic renal pedicle lymphatic disconnection for intractable chyluria
por: Liu, Bianjiang, et al.
Publicado: (2014) -
AB95. Epidemiology of post-transplant malignancy in Chinese renal transplant recipients
por: Zhang, Jian, et al.
Publicado: (2014)